Loxo Oncology, a prominent player in the biopharmaceutical industry, is headquartered in the United States and focuses on the development of targeted therapies for cancer treatment. Founded in 2013, the company has made significant strides in precision medicine, particularly in the field of oncology, with a commitment to addressing unmet medical needs. Loxo Oncology is renowned for its innovative approach to drug development, offering unique therapies that target specific genetic mutations in tumours. Their core products, including the well-regarded Vitrakvi (larotrectinib), exemplify their dedication to personalised medicine, setting them apart in a competitive market. With a strong presence in the US and expanding operations globally, Loxo has established itself as a leader in the oncology sector, achieving notable milestones in clinical trials and regulatory approvals.
We don't have data for Loxo, but we can show you information about their parent organization instead.
View parent company